IRVINE , Calif.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. AERI, a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class glaucoma therapies, today announced
that on September 23, dosing commenced of the first patients enrolled in
Rocket 4, the Company's fourth Phase 3 clinical trial of RhopressaTM,
a novel once-daily, triple-action eye drop being tested for its ability
to lower intraocular pressure (IOP) in patients with glaucoma or ocular
hypertension. Aerie anticipates total enrollment of approximately 700
patients in this two-arm 90-day efficacy study, comparing once-daily
RhopressaTM for non-inferiority to twice daily timolol. The
range for the primary endpoint mirrors Aerie's successful Rocket 2
trial, and includes patients with baseline IOPs ranging from above 20
mmHg (millimeters
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in